… 8 weeks of treatment, with an OBD of celecoxib of 600 mg bid. Conclusions: This study
defines the OBD of celecoxib when combined with a fixed dose of EGFR TKI. These results show …

… , phase 2 studies combining celecoxib with either erlotinib or … The sample size was
determined to achieve 80% power to … with targeted agents based on tumor biology can enrich the …

… This study will prospectively assess these and other biomarkers in … ) and celecoxib (a COX-2
inhibitor) in advanced NSCLC. This study established the optimal biologic dose of celecoxib …

… was related to the variable biology of the individual tumors … In summary, combining celecoxib
with docetaxel did not seem … used to titrate optimal COX-2 inhibition in future clinical trials. …

… study was to assess the response rate with the combination of gefitinib and … phase I study
seeking an optimal biological dose of celecoxib in combination with a standard dose of erlotinib…

… A phase I trial to determine the optimal biological dose of celecoxib when combined with
erlotinib in advanced non-small cell lung cancer. Clinical …

… 17 Clinical phase II studies suggested that a combination of the … , toxicity, cardiovascular
events, and biological markers. … day of chemotherapy for a maximum of 1 year. Treatment with …

… In summary, our observations with erlotinib and celecoxib combined with … A phase I trial to
determine the optimal biological dose of celecoxib when combined with erlotinib in advanced …

… on celecoxib/placebo treatment were studied to determine if the … In preclinical models, celecoxib
in combination with … One study indicated that maximum suppression of COX-2 activity, as …

… with advanced NSCLC, this study was designed to assess the … A maximum 14-day treatment
interruption was allowed with … Another study combining erlotinib with celecoxib in patients …